Could REVIVE THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:RVVTF) See a Reversal After Less Sellers Came In?

July 12, 2018 - By Robert Crowder

Revive Therapeutics Ltd. (OTCMKTS:RVVTF) Logo

The stock of REVIVE THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:RVVTF) registered a decrease of 75% in short interest. RVVTF’s total short interest was 300 shares in July as published by FINRA. Its down 75% from 1,200 shares, reported previously.

It closed at $0.139 lastly. It is down 0.00% since July 12, 2017 and is . It has underperformed by 12.57% the S&P500.

Revive Therapeutics Ltd. focuses on the development and commercialization of various drugs in Canada. The company has market cap of $7.88 million. The firm develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. It currently has negative earnings. The Company’s product pipeline also includes REV-003, a tianeptine for treatment of Rett Syndrome; and REV-004, a bucillamine for the treatment of cystinurial, as well as REV-005 for the treatment of WilsonÂ’s disease, which are under various stages of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: